Karyopharm Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Karyopharm Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Karyopharm Therapeutics Inc Strategy Report
- Understand Karyopharm Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Karyopharm Therapeutics Inc (Karyopharm) discovers and develops novel drugs for the treatment of cancer and other diseases. The company’s core technology harnesses the inhibition of nuclear export as a mechanism to treat patients suffering from cancer. Karyopharm’s lead product, Xpovio, is being developed for the treatment of multiple myeloma, and relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, eltanexor, verdinexor, and KPT-9274. Karyopharm’s drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.
Headquarters
United States of America
Address
2nd Floor, 85 Wells Avenue, Newton, Massachusetts, 02459-3298
Website
karyopharm.com
Telephone
1 617 6580600
No of Employees
325
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KPTI (NASD)
Revenue (2022)
$146.0M
-7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
13.4%
(2022 vs 2021)
Market Cap*
$160.7M
Net Profit Margin (2022)
XYZ
6.9%
(2022 vs 2021)
* As of and is in US$
Karyopharm Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Xpovio | Xpovio |
| Relapsed or Refractory Diffuse Large B-Cell Lymphoma. | |
| Relapsed or Refractory Multiple Myeloma | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate its proprietary investigational cereblon E3 ligase modulator (CELMoD) agent mezigdomide in combination with Karyopharm's selinexor. |
| 2023 | Regulatory Approval | In February, the company and the Menarini Group announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) granted full Marketing Authorization for NEXPOVIO. |
| 2023 | Contracts/Agreements | In January, the company announced a global collaboration with Foundation Medicine, Inc to develop FoundationOne CDx as a companion diagnostic for selinexor. |
Competitor Comparison
| Key Parameters | Karyopharm Therapeutics Inc | Amgen Inc | Incyte Corp | Shanghai Junshi Biosciences Co Ltd | Kite Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | China | United States of America |
| City | Newton | Thousand Oaks | Wilmington | Shanghai | Santa Monica |
| State/Province | Massachusetts | California | Delaware | Shanghai | California |
| No. of Employees | 325 | 26,700 | 2,524 | 2,568 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Paulson | Chief Executive Officer; President; Director | Executive Board | 2021 | 55 |
| Michael P. Mason | Chief Financial Officer; Executive Vice President; Treasurer | Senior Management | 2021 | 48 |
| James Accumanno | Chief Compliance Officer | Senior Management | 2022 | - |
| Reshma Rangwala, M.D., Ph.D. | Executive Vice President; Chief Medical Officer | Senior Management | 2022 | 45 |
| Sohanya Cheng | Executive Vice President; Chief Commercial Officer | Senior Management | 2021 | 40 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward